General
Preferred name
MELEVODOPA
Synonyms
L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride ()
Levomet ()
melevodopa / CHF-1301 ()
Melevodopa hydrochloride ()
L-DOPA methyl ester (hydrochloride) ()
CHF-1301 ()
P&D ID
PD014145
CAS
1421-65-4
7101-51-1
Tags
available
prodrug
drug
Drug Status
approved
experimental
investigational
Max Phase
2.0
Drug indication
Parkinson disease
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Precursor to L-DOPA that crosses the blood-brain barrier
(LOPAC library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
12
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
LOPAC library
Mcule NIBR MoA Box Subset
Natural product-based probes and drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
211.08
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
0.14
TPSA
92.78
Fraction CSP3
0.3
Chiral centers
1.0
Largest ring
6.0
QED
0.49
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
virtual
MOA
Dopamine Precursors
dopamine precursor, dopamine receptor agonist
Indication
Parkinson's Disease
Target
DDC
Biosynthetic Origin
Alkaloid, Other (Amino Acid), Other (Shikimate)
Therapeutic Class
CNS & PNS
Source data
